NANOBIOTIX (EPA:NANO) | WebDisclosure

Basculer en Français

10673	Companies
227607	Keywords
155996	Articles
120563	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 04/14/2025 at 22:15, 1 year 2 months ago

INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Communiqué de presse mensuel sur le nombre total de droits de vote et d'actions de Nanobiotix. Informations boursières et financières détaillées. Présentation de l'entreprise et de ses activités

Innovation Euronext Paris Droits De Vote Biotechnologie NANOBIOTIX
PRESS RELEASE

published on 04/14/2025 at 22:15, 1 year 2 months ago

Voting Rights and Shares Capital of the Company
Nanobiotix reports voting rights and shares capital updates. The late-stage biotech company aims to improve treatment outcomes through innovative therapies

Voting Rights Shares Capital Biotechnology Company NANOBIOTIX Treatment Outcomes
BRIEF

published on 03/27/2025 at 21:20, 1 year 3 months ago

Nanobiotix Unveils Phase 1 Data on NSCLC Therapy

NSCLC NBTXR3 Phase 1 Study Radioenhancer Clinical Trial Data
BRIEF

published on 03/27/2025 at 21:20, 1 year 3 months ago

Nanobiotix dévoile les données de phase 1 sur le traitement du cancer du poumon non à petites cellules

Étude De Phase 1 NBTXR3 CPNPC Radioenhancer Données Des Essais Cliniques
PRESS RELEASE

published on 03/27/2025 at 21:15, 1 year 3 months ago

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
Nanobiotix announces first data from the completed dose escalation part of a Phase 1 study evaluating NBTXR3 (JNJ-1900) as a 2L+ therapy for patients with locally advanced NSCLC. The study shows favorable safety and injection feasibility, with promising survival data

NSCLC NANOBIOTIX NBTXR3 Phase 1 Study Dose Escalation
PRESS RELEASE

published on 03/27/2025 at 21:15, 1 year 3 months ago

Nanobiotix annonce les premières données issues de la partie escalade de dose completée d’une étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en traitement de 2L+ pour les patients atteints d’un CPNPC localement avancé
Nanobiotix annonce les premières données prometteuses de l'étude de phase 1 évaluant JNJ-1900 (NBTXR3) en traitement de 2L+ pour les patients atteints d'un CPNPC localement avancé

Traitement NANOBIOTIX CPNPC Phase 1 JNJ-1900
BRIEF

published on 03/20/2025 at 21:20, 1 year 3 months ago

Nanobiotix dévoile des résultats de Phase 1 au Congrès Européen sur le Cancer du Poumon

Biotechnologie NANOBIOTIX Cancer Du Poumon Phase 1 JNJ-1900
BRIEF

published on 03/20/2025 at 21:20, 1 year 3 months ago

Nanobiotix Unveils Phase 1 Results at European Lung Cancer Congress

Biotechnology NANOBIOTIX Lung Cancer Phase 1 JNJ-1900
PRESS RELEASE

published on 03/20/2025 at 21:15, 1 year 3 months ago

NANOBIOTIX annonce la présentation de données issues de deux études de phase 1 évaluant JNJ-1900 (NBTXR3) lors du Congrès Européen sur le Cancer du Poumon
Nanobiotix annonce la présentation de données de deux études de Phase 1 évaluant JNJ-1900 (NBTXR3) lors du Congrès Européen sur le Cancer du Poumon 2025

NANOBIOTIX Cancer Du Poumon JNJ-1900 Études De Phase 1 ELCC 2025
PRESS RELEASE

published on 03/20/2025 at 21:15, 1 year 3 months ago

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
Nanobiotix announces presentation of data from two Phase 1 studies evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference. Studies highlight safety, efficacy, and collaboration strategies

Collaboration NANOBIOTIX Lung Cancer JNJ-1900 Phase 1 Studies

Accesswire

Published on 07/01/2026 at 17:00, 4 hours 58 minutes ago

Notification of Relevant Change to Significant Shareholder
Published on 07/01/2026 at 14:30, 7 hours 28 minutes ago

AIAI Holdings' MediGuide Launches Digital Platform
Published on 07/01/2026 at 13:30, 8 hours 28 minutes ago

Sidney Resources Corporation Appoints Former Idaho Governor C.L. "Butch" Otter as Chairman of the Board
Published on 07/01/2026 at 13:00, 8 hours 58 minutes ago

Fox River Issues Shares Pursuant to Exploration Agreement in Connection with Impending Arrangement
Published on 07/01/2026 at 03:15, 18 hours 43 minutes ago

GLG Life Tech Corporation Announces 2026 AGM Voting Results

View all ACCESSWIRE

EQS Group

Published on 07/01/2026 at 20:40, 1 hour 18 minutes ago

KNDS to resume its Initial Public Offering process when Capital Markets conditions are supportive
Published on 07/01/2026 at 20:04, 1 hour 53 minutes ago

2CRSi SA: 2CRSi engage une procédure de vérification indépendante relative à son contrat allemand.
Published on 07/01/2026 at 20:04, 1 hour 53 minutes ago

2CRSi SA: 2CRSi initiates an independent verification procedure regarding its German contract.
Published on 07/01/2026 at 19:00, 2 hours 58 minutes ago

PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 07/01/2026 at 19:00, 2 hours 58 minutes ago

OLB strengthens its leadership team to drive the next phase of growth

Les Echos

Published on 07/01/2026 at 19:40, 2 hours 17 minutes ago

Initiation de couverture du titre Solocal par Portzamparc
Published on 07/01/2026 at 18:40, 3 hours 18 minutes ago

LNA SANTE : Acquisition de 5 EHPAD
Published on 07/01/2026 at 18:26, 3 hours 32 minutes ago

Modula renews its confidence in AMA with a four-year agreement integrating XpertEye’s new AI-powered features
Published on 07/01/2026 at 18:26, 3 hours 32 minutes ago

Modula renouvelle sa confiance à AMA avec un contrat de quatre ans intégrant les nouvelles fonctionnalités IA d’XpertEye
Published on 07/01/2026 at 18:01, 3 hours 57 minutes ago

Covivio Hotels - Informations relatives au nombre total de droits de vote et d’actions composant le capital social

View all LES ECHOS COMFI WIRE